» Articles » PMID: 33106295

Competing Substrates for the Bifunctional Diaminopimelic Acid Epimerase/Glutamate Racemase Modulate Peptidoglycan Synthesis in Chlamydia Trachomatis

Overview
Journal Infect Immun
Date 2020 Oct 27
PMID 33106295
Authors
Affiliations
Soon will be listed here.
Abstract

The genome encodes multiple bifunctional enzymes, such as DapF, which is capable of both diaminopimelic acid (DAP) epimerase and glutamate racemase activity. Our previous work demonstrated the bifunctional activity of chlamydial DapF and in a heterologous system (). In the present study, we employed a substrate competition strategy to demonstrate DapF function in We reasoned that, because DapF utilizes a shared substrate-binding site for both racemase and epimerase activities, only one activity can occur at a time. Therefore, an excess of one substrate relative to another must determine which activity is favored. We show that the addition of excess l-glutamate or -DAP (DAP) to resulted in 90% reduction in bacterial titers, compared to untreated controls. Excess l-glutamate reduced synthesis of DAP by to undetectable levels, thus confirming that excess racemase substrate led to inhibition of DapF DAP epimerase activity. We previously showed that expression of in a (racemase) Δ (epimerase) double mutant of rescues the d-glutamate auxotrophic defect. Addition of excess DAP inhibited growth of this strain, but overexpression of allowed the mutant to overcome growth inhibition. These results confirm that DapF is the primary target of these DAP and l-glutamate treatments. Our findings demonstrate that suppression of either the glutamate racemase or epimerase activity of DapF compromises the growth of Thus, a substrate competition strategy can be a useful tool for validation of an essential bifunctional enzyme.

Citing Articles

Screening and Identification of Natural Compounds as Potential Inhibitors of Glutamate Racemase, an Emerging Drug Target of Food Pathogen O157:H7: An Approach to Combat Increasing Drug Resistance.

Kumar R, Gupta S, Adhana S, Khanna A, Sahoo S, Faiza M Infect Disord Drug Targets. 2024; 25(2):e18715265306131.

PMID: 39161148 DOI: 10.2174/0118715265306131240809095241.

References
1.
Lovering A, Safadi S, Strynadka N . Structural perspective of peptidoglycan biosynthesis and assembly. Annu Rev Biochem. 2012; 81:451-78. DOI: 10.1146/annurev-biochem-061809-112742. View

2.
Liu L, Yoshimura T, Endo K, Kishimoto K, Fuchikami Y, Manning J . Compensation for D-glutamate auxotrophy of Escherichia coli WM335 by D-amino acid aminotransferase gene and regulation of murI expression. Biosci Biotechnol Biochem. 1998; 62(1):193-5. DOI: 10.1271/bbb.62.193. View

3.
Liechti G, Kuru E, Hall E, Kalinda A, Brun Y, VanNieuwenhze M . A new metabolic cell-wall labelling method reveals peptidoglycan in Chlamydia trachomatis. Nature. 2013; 506(7489):507-10. PMC: 3997218. DOI: 10.1038/nature12892. View

4.
McCoy A, Adams N, Hudson A, Gilvarg C, Leustek T, Maurelli A . L,L-diaminopimelate aminotransferase, a trans-kingdom enzyme shared by Chlamydia and plants for synthesis of diaminopimelate/lysine. Proc Natl Acad Sci U S A. 2006; 103(47):17909-14. PMC: 1693846. DOI: 10.1073/pnas.0608643103. View

5.
Singh R, Liechti G, Slade J, Maurelli A . Chlamydia trachomatis Oligopeptide Transporter Performs Dual Functions of Oligopeptide Transport and Peptidoglycan Recycling. Infect Immun. 2020; 88(5). PMC: 7171251. DOI: 10.1128/IAI.00086-20. View